A review of the role of anti‐opioid peptides in morphine tolerance and dependence

Synapse

Volumn 12, Issue 2, 1992, Pages 129-138

  Rothman, Richard B ^a  

^a NIDA Addiction Research Center   (United States)

Author keywords

CCK 8; FRMF NH2; Opioid dependence; Opioid receptors

Indexed keywords

DYNORPHIN; MORPHINE; NALOXONE; NEUROPEPTIDE; NEUROPEPTIDE FF; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; MORPHINE ADDICTION; MORPHINE TOLERANCE; NONHUMAN; REVIEW;

ANIMAL; DRUG TOLERANCE; DYNORPHINS; ENDORPHINS; HUMAN; MORPHINE; NEUROPEPTIDES; OLIGOPEPTIDES; SUBSTANCE-RELATED DISORDERS;

EID: 0026784599     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.890120206     Document Type: Article

References (109)

1. Dynorphin‐(1‐13): effects in nontolerant and morphine‐dependent rhesus monkeys
2. Characterization of rat spinal cord receptors to FLFQPQRF‐amide, a mammalian morphine modulating peptide: a binding study
3. Characterization and localization of a putative morphine‐modulating peptide, FLFQPQRFamide, in the rat spinal cord: biochemical and immunocytochemical studies
4. Evidence that the aversive effects of opioid antagonists and kappa‐agonists are centrally mediated
5. A novel action of morphine in the rat locus coeruleus: persistent decrease in adenylate cyclase
6. Interactions of thyrotropin releasing hormone, its metabolites and analogues with endogenous and exogenous opiates
7. Chronic morphine increases m‐opiate receptor binding in rat brain: a quantitative autoradiographic study
8. Multple opiate receptors. Enkephalins and morphine bind to receptors of different specificity
9. Opioid peptides induce reduction of enkephalin receptors in cultured neuroblastoma cells
10. Specific receptor for the opioid peptide dynorphin: structure‐activity relationships
11. Opioid receptor reserve in normal and morphine‐tolerant guinea pig ileum myenteric plexus
12. Dynorphin is a specific endogenous ligand of the kappa opioid receptor
13. A general theory of the genesis of drug dependence by induction of receptors
14. Effect of prolyl‐leucyl‐glycinamide and alpha‐melanocyte‐stimulating hormone on levorphanol‐induced analgesia, tolerance and dependence
15. Antagonism of morphine‐induced analgesia, tolerance and dependence by alpha‐melanocyte‐stimulating hormone
16. Dynorphin and dynorphin are ligands for the kappa‐subtype of opiate receptor
17. Opioids can evoke direct receptor mediated excitatory effects on sensory neurons
18. Receptor adaptations to centrally administered drugs
19. Chronic administration of morphine and naltrexone up‐regulate 3H‐[D‐ala2, D‐leu5]enkephalin binding sites by different mechanisms
20. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats
21. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
22. Implications of methadone maintenance for theories of narcotic addiction
23. Blockade of CCK‐induced hypophagia and prevention of morphine tolerance by the CCK antagonist L‐364, 718
24. The selective CCK‐B receptor antagonist L‐365, 260 enhances morphine analgesia and prevents morphine tolerance in the rat
25. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia
26. Opiate antagonist function of cholecystokinin in analgesia and energy balance systems
27. Naltrexone treatment–the problem of patient acceptance
28. Dynorphin: a possible modulatory peptide on morphine or beta‐endorphin analgesia in mouse
29. Intracerebroventricular analgesia enhanced by intrathecal (IT) dynorphin A(1‐17) antibody
30. Clonidine, administered intracerebroventricularly in mice, produces an anti‐analgesic effect which may be mediated spinally by dynorphin A(1‐17)
31. Spinal dynorphin A(1‐17): possible mediator of antianalgesic action
32. Systemic single dose morphine pretreatment desensitizes mice to the spinal antianalgesic action of dynorphin A(1‐17)
33. Existence of antiopiate systems as illustrated by MIF‐1/Tyr‐MIF‐1
34. Tyr‐MIF‐1 attenuates antinociceptive responses induced by three models of stress‐analgesia
35. The inhibitory effect of presynaptic alpha‐adrenoreceptor agonists on contractions of guinea pig ileum and mouse vas deferens in the morphine‐dependent and withdrawn states produced in vitro
36. Drug tolerance and physical dependence
37. Dynorphin‐(1‐13), an extraordinarily potent opioid peptide
38. Electrophysiological effects of FLFQPQRF amide, an endogenous brain morphine modulating peptide, on cultured mouse spinal‐cord neurons
39. Beta‐endorphin(1‐27) is an antagonist of beta‐endorphin analgesia
40. Mismatches between neurotransmitter and receptor localizations in brain: observations and implications
41. Modulation of mu‐mediated antinociception by delta agonists: characterization with antagonists
42. Repeated electroconvulsive shock or chronic morphine increases the number of 3H‐D‐ala2, D‐leu5‐enkephalin binding sites in rat brain
43. In vivo interactions among opiate receptor agonists and antagonists
44. Thyrotropin releasing hormone antagonizes b‐endorphin hypothermia and catalepsy
45. Suppressive effect of cholecystokinin and its related peptides on b‐endorphin catalepsy in rats
46. Opioid agonist and antagonist antinociceptive properties of [D‐Ala2, Leu5, Cys6]enkephalin: selective actions at the delta noncomplexed site
47. MIF‐1's differential actions as an opiate antagonist
48. Tyr‐MIF‐1 acts as an opiate antagonist in the tail‐flick test
49. IgG from antiserum against endogenous mammalian FRMF‐NH2‐related peptides augments morphine‐and stress‐induced analgesia in mice
50. Immunohistochemical distribution and partial characterization of FLFQPQRFamide like peptides in the central nervous system of rats
51. Cellular and molecular mechanisms of drug dependence
52. Characterization of opioid receptors in nervous tissue
53. In vitro models in the study of structure‐activity relationships of narcotic analgesics
54. Tolerance and dependence: implications for the pharmacological treatment of addiction
55. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo
56. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat
57. Opiate receptor downregulation and desensitization in neuroblastoma X glioma NG108‐15 hybrid cells are two separate cellular adaptation processes
58. Comparison of opiate inhibition of adenylate cyclase activity in neuroblastoma N18TG2 and neuroblastoma x glioma NG108‐15 hybrid cell lines
59. 3H‐leu5‐enkephalin specific binding to synaptic membranes: comparison with 3H‐dihydromorphine and 3H‐naloxone
60. Buprenorphine has potent kappa opioid receptor antagonist activity
61. Opiate and peptide interaction: effect of enkephalins on morphin analgesia
62. Separation of morphine analgesia from physical dependence
63. Endogenous opioid peptides: multiple agonists and receptors
64. Differential interactions of cholecystokinin and FLFQPQRF‐NH2 with m and d opioid antinociception in the rat spinal cord
65. 2‐like peptides in spinal cords of various mammalian species using specific radioimmunoassays
66. 2, a mammalian FMRF‐NH2‐like peptide
67. Analog of neuropeptide FF attenuates morphine abstinence syndrome
68. 2‐like mammalian peptide precipitates opiate‐withdrawl syndrome in the rat
69. 2‐like mammalian octapeptide in opiate dependence and withdrawal
70. 2‐like mammalian octapeptide: possible role in opiate dependence and abstinence
71. Regulation of G proteins by chronic morphine in the rat locus coeruleus
72. Beta‐endorphin‐induced analgesia is inhibited by synthetic analogs of beta‐endorphin
73. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels
74. Neuroanatomy of morphine‐modulating peptides
75. Psychotomimesis mediated by kappa opiate receptors
76. 2) and related peptides on mammals
77. Opiate receptors
78. A quantitative study of [3H]D‐Ala2‐D‐Leu5‐enkephalin binding to rat brain membranes. Evidence that oxymorphine is a noncompetitive inhibitor of the lower affinity delta‐binding site
79. Chronic administration of morphine and naltrexone up‐regulate opioid binding sites labeled by 3H‐[D‐ala2‐MePhe4, Gly‐ol5]enkephalin: evidence for two mu binding sites
80. Allosteric coupling among opioid receptors: evidence for an opioid receptor complex
81. Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824
82. Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence
83. Chronic morphine up‐regulates a mu‐opiate binding site labeled by 3H‐cycloFOXY: a novel opiate antagonist suitable for positron emission tomography
84. Upregulation of rat brain opioid receptors by the chronic administration of morphine: possible evidence for an anti‐opiate model of tolerance and dependence
85. Opioid tolerance and dependence in light of the multiplicity of opioid receptors
86. Opioid dependence and cross‐dependence in the isolated guinea pig ileum
87. Lack of cross‐tolerance on multiple opiate receptors in the mouse vas deferens
88. Morphine receptors are regulators of adenylate cyclase activity
89. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance
90. Differential modulation by [D‐Pen2, D‐Pen5]enkephalin and dynorphin (A‐1‐17) of the inhibitory bladder motility effects of selected mu agonists in vivo
91. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism
92. Effects of cocaine on extrapyramidal and limbic dynorphin systems
93. Role of opioid receptors in narcotic tolerance/dependence
94. Antagonism of morphine antinociception by intrathecally administered corticotropin‐releasing factor in mice
95. 2‐like immunoreactivity
96. Neurochemical and functional correlates of naltrexone‐induced opiate receptor up‐regulation
97. Changes in prodynorphin peptide content following treatment with morphine or amphetamine: possible role in mechanisms of action of drug of abuse
98. Regulation of striatonigral prodynorphin peptides by dopaminergic agents
99. Release of immunoreactive Met‐enkephalin from the spinal cord by intraventricular beta‐endorphin but not morphine in anesthetized rats
100. Brain peptides with opiate antagonist action: possible role in tolerance and dependence
101. A further characterization of the differential effects of leucine enkephalin, methionine, enkephalin and their analogs on morphin‐induced analgesia
102. Quantitative aspects of abstinence in morphine‐dependent rats
103. Opioid tolerance and dependence: reevaluating the unitary hypothesis
104. FMRF‐NH2‐like peptides antiopiates
105. Isolation, sequencing, synthesis and pharmacological characterization of two brain neuropeptides that modulate the actions of morphine
106. Methadone maintenance in the 3 Treatment of opioid dependence. A current perspective